Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Toldo, Stefano ^a   Goehe, Rachel W ^a   Lotrionte, Marzia ^b   Mezzaroma, Eleonora ^a   Sumner, Evan T ^a   Biondi Zoccai, Giuseppe G L ^c   Seropian, Ignacio M ^a   Van Tassell, Benjamin W ^a   Loperfido, Francesco ^b   Palazzoni, Giovanni ^b   Voelkel, Norbert F ^a   Abbate, Antonio ^a   Gewirtz, David A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CASPASE 3; CASPASE 7; DNA; DOXORUBICIN; EPIRUBICIN; GAMMA HISTONE H2AX; HISTONE H2AX; NON PEGYLATED LIPOSOMAL DOXORUBICIN; REACTIVE OXYGEN METABOLITE; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARDIOTOXICITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOUBLE STRANDED DNA BREAK; DRUG MONITORING; DRUG SENSITIVITY; ENZYME ACTIVITY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART OUTPUT; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; HUMANS; MALE; MICE; MYOCYTES, CARDIAC; REACTIVE OXYGEN SPECIES;

EID: 84875013783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058421     Document Type: Article

References (31)

1. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, et al. (2011) Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103: 714-36.
2. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, et al. (2004) Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101: 3-27.
3. Fernández A, Sessel S, (2009) Selective antagonism of anticancer drugs for side-effect removal. Trends Pharmacol Sci. 30: 403-10.
4. Sreeramoju P, Libutti SK, (2010) Strategies for targeting tumors and tumor vasculature for cancer therapy. Adv Genet. 69: 135-52.
5. Henderson IC (2011) Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park) 25: 115-24, 127.
6. Shan K, Lincoff AM, Young JB, (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med. 125: 47-58.
7. Cortés-Funes H, Coronado C, (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 7: 56-60.
8. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomized controlled trials. BMC Cancer 10: 337.
9. Solaini G, Ronca G, Bertelli A, (1985) Studies on the effects of anthracyclines on mitochondrial respiration in vitro. Drugs Exp Clin Res. 11: 115-21.
10. Berthiaume JM, Wallace KB, (2007) Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23: 15-25.
11. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
12. Neri B, Cini-Neri G, D'Alterio M, (1984) Effect of anthracyclines and mitoxantrone on oxygen uptake and ATP intracellular concentration in rat heart slices. Biochem Biophys Res Commun 125: 954-60.
13. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, et al. (2004) Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 15: 1527-34.
14. Lotrionte M, Palazzoni G, Natali R, Comerci G, Abbate A, et al. (2007) Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy. Minerva Cardioangiol 55: 711-20.
15. Lotrionte M, Palazzoni G, Abbate A, De Marco E, Mezzaroma E, et al. (2012) Int J Cardiol - in press.
16. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, et al. (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979-84.
17. Kuo LJ, Yang LX, (2008) Gamma-H2AX- a novel biomarker for DNA double-strand breaks. In Vivo 22: 305-9.
18. Toldo S, Bogaard HJ, Van Tassell BW, Mezzaroma E, Seropian IM, et al. (2011) Right ventricular dysfunction following acute myocardial infarction in the absence of pulmonary hypertension in the mouse. PLoS One 6: e18102.
19. Gardin JM, Adams DB, Douglas PS, Feigenbaum H, Forst DH, et al. (2002) Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr 15: 275-90.
20. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B, (2012) Anthracyclines and mitochondria. Adv Exp Med Biol 942: 385-419.
21. Gewirtz DA, (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-41.
22. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15: 1544-52.
23. Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S, (2009) Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 18: 218-24.
24. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, et al. (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11Suppl 1: S21-36.
25. Salvatorelli E, Menna P, Gianni L, Minotti G, (2007) Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. J Pharmacol Exp Ther 320: 790-800.
26. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS, (1998) Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101: 812-818.
27. Schäfer M, Pönicke K, Heinroth-Hoffmann I, Brodde OE, Piper HM, et al. (2001) Beta-adrenoceptor stimulation attenuates the hypertrophic effect of alpha-adrenoceptor stimulation in adult rat ventricular cardiomyocytes. J. Am. Coll. Cardiol 37: 300-307.
28. Montaigne D, Hurt C, Neviere R, (2012) Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem Res Int 2012: 951539.
29. Hoyano Y, Furukawa Y, Oguchi T, Kasama M, Imamura H, et al. (1996) Acute presynaptic inhibition by doxorubicin of negative chrono- and inotropic responses to parasympathetic nerve stimulation in isolated, blood-perfused dog atrium. J Cardiovasc Pharmacol 27: 37-41.
30. L'Ecuyer T, Horenstein MS, Thomas R, Vander Heide R, (2001) Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies. Mol Genet Metab 74: 370-9.
31. Strigun A, Wahrheit J, Niklas J, Heinzle E, Noor F, (2012) Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis. Toxicol Sci 125: 595-606.